Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…

If all baby boomers got tested for hep C, that could help stem freefall of Gilead's blockbusters—and it's exactly the move the company is…

Activist investors have moved in on Bristol-Myers Squibb, including Carl Icahn, who has a long history of pushing drugmakers to put themselves on the block.

J&J is the most admired pharma company, according to Fortune's annual corporate poll, for the fourth year in a row and comes in at No. 13 among all…

AbbVie’s former blockbuster AndroGel faces a class-action lawsuit over side effects—and a trial of a different sort as new testosterone-replacement data paint…

Celgene’s late-stage pill, ozanimod, could hit $2b in sales and add pressure to an already competitive oral MS market, analysts say.

AstraZeneca snagged $250 million-plus for its cancer drug Zoladex in the U.S., where it brought in only $69 million last year. The deal, AZ's latest slim-…

Masking depression is never a good idea. Otsuka and Lundbeck are back on the air to make that case with a new TV ad for antipsychotic Rexulti.

President Trump told Robert Kennedy Jr. he won't "back down" from plans to create vax safety commission, despite guaranteed "uproar"…

Marketing